Opiant Pharmaceuticals, Inc.
OPNT · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $41 | $27 | $38 | $14 |
| % Growth | 48.6% | -28.3% | 183% | – |
| Cost of Goods Sold | $9 | $6 | $8 | $1 |
| Gross Profit | $32 | $21 | $31 | $12 |
| % Margin | 77.7% | 77.4% | 79.8% | 89% |
| R&D Expenses | $17 | $9 | $9 | $8 |
| G&A Expenses | $12 | $12 | $12 | $11 |
| SG&A Expenses | $17 | $16 | $13 | $11 |
| Sales & Mktg Exp. | $5 | $5 | $1 | $214 |
| Other Operating Expenses | -$7 | -$2 | -$2 | $13 |
| Operating Expenses | $27 | $23 | $20 | $33 |
| Operating Income | $5 | -$2 | $11 | -$21 |
| % Margin | 12.7% | -8.2% | 28.5% | -156.8% |
| Other Income/Exp. Net | -$2 | -$0 | $0 | $46 |
| Pre-Tax Income | $3 | -$2 | $11 | -$21 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | $3 | -$2 | $12 | -$21 |
| % Margin | 7.4% | -6.8% | 30.3% | -156.8% |
| EPS | 0.68 | -0.44 | 2.88 | -7.1 |
| % Growth | 254.5% | -115.3% | 140.6% | – |
| EPS Diluted | 0.51 | -0.44 | 2.17 | -7.1 |
| Weighted Avg Shares Out | 4 | 4 | 4 | 3 |
| Weighted Avg Shares Out Dil | 6 | 4 | 5 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | $6 | -$2 | $11 | -$21 |
| % Margin | 14.3% | -5.6% | 29.2% | -156.4% |